- Home
- VCSA vs ATOS Comparison
VCSA vs ATOS Comparison
Compare VCSA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCSA
- ATOS
- Stock Information
- Founded
- VCSA 2009
- ATOS 2009
- Country
- VCSA United States
- ATOS United States
- Employees
- VCSA N/A
- ATOS N/A
- Industry
- VCSA Computer Software: Prepackaged Software
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- VCSA Technology
- ATOS Health Care
- Exchange
- VCSA Nasdaq
- ATOS Nasdaq
- Market Cap
- VCSA 82.3M
- ATOS 96.8M
- IPO Year
- VCSA N/A
- ATOS 2012
- Fundamental
- Price
- VCSA $5.42
- ATOS $0.62
- Analyst Decision
- VCSA Hold
- ATOS Strong Buy
- Analyst Count
- VCSA 3
- ATOS 3
- Target Price
- VCSA $5.00
- ATOS $7.00
- AVG Volume (30 Days)
- VCSA 232.5K
- ATOS 699.0K
- Earning Date
- VCSA 05-08-2025
- ATOS 05-12-2025
- Dividend Yield
- VCSA N/A
- ATOS N/A
- EPS Growth
- VCSA N/A
- ATOS N/A
- EPS
- VCSA N/A
- ATOS N/A
- Revenue
- VCSA $910,485,000.00
- ATOS N/A
- Revenue This Year
- VCSA N/A
- ATOS N/A
- Revenue Next Year
- VCSA $3.32
- ATOS N/A
- P/E Ratio
- VCSA N/A
- ATOS N/A
- Revenue Growth
- VCSA N/A
- ATOS N/A
- 52 Week Low
- VCSA $2.07
- ATOS $0.55
- 52 Week High
- VCSA $8.19
- ATOS $1.81
- Technical
- Relative Strength Index (RSI)
- VCSA 56.64
- ATOS 42.51
- Support Level
- VCSA $5.34
- ATOS $0.56
- Resistance Level
- VCSA $5.50
- ATOS $0.67
- Average True Range (ATR)
- VCSA 0.13
- ATOS 0.06
- MACD
- VCSA -0.01
- ATOS 0.00
- Stochastic Oscillator
- VCSA 26.47
- ATOS 43.75
About VCSA Vacasa Inc.
Vacasa Inc is a vacation rental management platform in North America, transforming the vacation rental experience by integrating purpose-built technology with expert local and national teams.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.